Dr Jodi Law Woan-Fei is an Assistant Professor in Life Science and Healthcare at Nottingham Ningbo China Beacons of Excellence Research and Innovation Institute (CBI), University of Nottingham Ningbo China. She holds a PhD in Medicine (Biomedical Science), awarded by Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia in 2019. She is a board-certified Graduate Technologist (MBOT) and a member of the Royal Society of Biology, United Kingdom (MRSB). 

She is trained in biosystematics studies of novel Streptomyces and exploring their beneficial biological activities (e.g., anticancer, antioxidant, antibacterial, probiotic strains), which can be the sources of potential drug candidates to improve human health and wellbeing. She is a passionate researcher with great interest in expanding her research. She has been studying microbes of environmental origins, and now she is exploring the microbes from the human body (human microbiome). She is actively working on research involving the investigation of antibiotic-resistant gut bacterial pathogens and their relationship with disease development. She firmly believes that understanding the gut pathogens is crucial for developing effective microbiome-based treatment options. 

Dr Jodi Law embarked on her research journey in 2014 with her honours degree project, focusing on detecting foodborne pathogens from seafood. During her honours study, she found her passion in research, which eventually sparked her interest in pursuing her PhD, with a project focusing on discovering beneficial and novel microbes from nature—mangrove forest in Sarawak.

She completed her doctoral thesis entitled “Diversity and Biosystematics of Novel Streptomyces from Mangrove in Sarawak”. The significant outcomes of her research include the discovery of two novel Streptomyces strains: Streptomyces monashensis (referring to Monash University) and Streptomyces colonosanans (referring to colon-healing) with potent anti-colon cancer and antioxidant activities.

Her research interests include the (1) biosystematics studies of novel bioactive Streptomyces and (2) investigating the intricate connections between the human microbiome and its impact on health and disease. In particular, the detection and identification of antibiotic-resistant bacterial pathogens from the gut microbiome associated with disease development and to generate potential microbiome-based treatment options (e.g. probiotics).